Long-acting and short-acting benzodiazepines in the elderly: kinetic differences and clinical relevance

1984 ◽  
Vol 8 (sup4) ◽  
pp. 94-107 ◽  
Author(s):  
R. Bandera ◽  
P. Bollini ◽  
S. Garattini
DICP ◽  
1989 ◽  
Vol 23 (7-8) ◽  
pp. 610-613 ◽  
Author(s):  
Ronald B. Stewart ◽  
Franklin E. May ◽  
Mary T. Moore ◽  
William E. Hale

Psychotropic drug use was evaluated in 2022 ambulatory elderly subjects in 1978-80 and again in 1984-86. Use of hypnotic drugs declined from 8.5 percent (n = 3234) in 1978-80 to 6.3 percent (n = 2681) in 1984-86 (p<0.01). Use of the long-acting hypnotic flurazepam decreased (p <0.01) and use of two short-acting drugs, triazolam and temazepam, increased. Prescribing of long half-life benzodiazepines, such as diazepam (p<0.01) and chlordiazepoxide, clorazepate, halazepam, and prazepam as a group (p <0.01) decreased as well as the use of nearly all products containing barbiturates (p<0.01).


2013 ◽  
Vol 29 (10) ◽  
pp. 840-845 ◽  
Author(s):  
Andrea L. Rubinstein ◽  
Diane M. Carpenter ◽  
Jerome R. Minkoff

2021 ◽  
Author(s):  
Jorge Machado Alba

Introduction: Chronic obstructive pulmonary disease (COPD) affects approximately 174 million people worldwide.The objective was to determine the trends of the use of medications for COPD in a group of Colombian patients. Methods: This was a retrospective study on prescription patterns of bronchodilators and other medications used in COPD from a population database with follow-up at 12 and 24 months. Patients older than 18 years of age of any sex who had COPD between 2017 and 2019 were included. Sociodemographic variables, medications, treatment schedules for COPD, comorbidities, comedications, and the specialty of the prescriber were considered. Results: A total of 9,476 people with a diagnosis of COPD were evaluated. They had a mean age of 75.9 ± 10.7 years, 50.1% were men, and 86.8% were prescribed by a general practitioner. At the beginning of the follow-up, on average, they received 1.6 medications/patient, mainly short-acting antimuscarinics (3784; 39.9%), followed by short-acting β-agonists (2997, 31.6%) and inhaled corticosteroids (ICS) (2239, 23.6%), but 5083 (53.6%) patients received a long-acting bronchodilator. At the beginning of the follow-up, 645 (6.8%) patients were put on triple therapy with antimuscarinics, β-agonists, and ICS, and at 12 months, this rose to 1388 (20.6%). A total of 57.9% had comorbidities, most often hypertension (44.4%). Conclusions: This group of patients with COPD treated in Colombia frequently received short-acting bronchodilators and ICS, but a growing proportion are undergoing controlled therapy with long-acting bronchodilators, a situation that can improve the indicators of morbidity, exacerbations, and hospitalization.


1966 ◽  
Vol 4 (13) ◽  
pp. 52-52

This article stated that Actrapid and Nuso insulins can be mixed with protamine zinc insulin and other long-acting insulins. This is true, but we should have made it clear that in such a mixture the time-action characteristics of its components are likely to be altered, for some of the short-acting insulin is probably bound by the long-acting one.


1994 ◽  
Vol 28 (10) ◽  
pp. 1159-1161 ◽  
Author(s):  
Preston P. Purdum ◽  
Stacey L. Shelden ◽  
John W. Boyd ◽  
Mitchell L. Shiffman

OBJECTIVE: To report oxaprozin-induced fulminant hepatic failure. CASE SUMMARY: A 56-year-old woman was admitted with fulminant hepatic failure. Work-up for potential etiologies was negative except for the use of oxaprozin for the preceding two months. Results of premortem liver biopsy were consistent with drug-induced hepatic injury similar to that previously reported with diclofenac. DISCUSSION: Although the literature describes elevation in hepatic transaminase concentrations associated with oxaprozin, fulminant hepatic failure has not been described previously. CONCLUSIONS: Elevations in hepatic transaminase concentrations and now fulminant hepatic failure have been shown to occur with oxaprozin, as previously seen with other nonsteroidal antiinflammatory drugs (NSAIDs). Transaminitis is a known adverse effect of NSAID use, but is usually mild and reversible with discontinuation of drug. Transaminitis may be more likely to occur in the elderly, in patients receiving concurrent potentially hepatotoxic medications, and possibly with the newer long-acting NSAIDs. The existence of fulminant hepatitis, although rare, supports the need for monitoring liver function enzymes during NSAID therapy.


Sign in / Sign up

Export Citation Format

Share Document